Advancing medicines for metabolic health
Zealand Pharma (zealandpharma.com) earns a Brand Analyzer score of 77 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 3448 Healthcare brands analyzed, Zealand Pharma ranks in the 71st percentile (category average 72, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 72/100, Digital Presence 94/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 87/100, AI Discoverability 67/100, Brand Authority 41/100.
Zealand Pharma is a Danish biotechnology company headquartered in Glostrup, founded in 1998. The company discovers, designs, and develops peptide-based and small molecule medicines, with a primary focus on obesity and metabolic health, as well as conditions such as Congenital Hyperinsulinism and Short Bowel Syndrome. It positions itself as a company dedicated exclusively to transforming metabolic health outcomes, serving patients, healthcare providers, biotech partners, and investors.
| Brand Name | Zealand Pharma |
|---|---|
| Domain | zealandpharma.com |
| Industry | Healthcare |
| Founded | 1998 |
| Headquarters | Glostrup |
| Parent Company / Owner | Legg Mason |
| CEO | Britt Meelby Jensen |
| Main Competitors | Novo Nordisk (88/100), Eli Lilly (78/100), Amgen (82/100), Pfizer (89/100), Boehringer Ingelheim (76/100), Structure Therapeutics (71/100), Altimmune (81/100) |
Moz Domain Authority 47/100 vs category average 35 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #929,202 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Zealand Pharma has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Zealand Pharma is a biotechnology company focused on advancing medicines for obesity and metabolic health" (Meta description: 15 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on LinkedIn, Instagram, GitHub; no detected presence on X (Twitter), Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Zealand Pharma scores 53/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Zealand Pharma has a limited AI-visibility profile at 53/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (19/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #929,202 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Zealand Pharma from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Zealand Pharma?", Claude could identify the brand as of August 2026. Zealand Pharma is a Danish biotechnology company based in Copenhagen that specializes in the discovery and development of peptide-based medicines, particularly for metabolic and gastrointestinal diseases. It's known for developing glepaglutide for short bowel syndrome and has par Best known for Peptide-based drug development for metabolic diseases, including obesity and short bowel syndrome treatments.
When asked "Best brands similar to Zealand Pharma?", Claude would recommend Zealand Pharma as of August 2026. It's a notable player in peptide therapeutics and the obesity/metabolic disease space, relevant alongside companies like Novo Nordisk when discussing GLP-1 drug development.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Zealand Pharma's main competitors include Novo Nordisk (88/100), Eli Lilly (78/100), Amgen (82/100), Pfizer (89/100), Boehringer Ingelheim (76/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Zealand Pharma and Pfizer are competitors in Healthcare. Brand Analyzer scores Zealand Pharma at 77/100 and Pfizer at 89/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Zealand Pharma include Novo Nordisk (88/100), Eli Lilly (78/100), Amgen (82/100), Pfizer (89/100), Boehringer Ingelheim (76/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Zealand Pharma is a Danish biotechnology company, founded in 1998 and headquartered in Glostrup, Denmark. It specializes in the discovery, design, and development of peptide-based and small molecule medicines, with a primary focus on obesity and related metabolic health conditions.
Sources: Zealand Pharma official site
Zealand Pharma has moderate AI-search visibility, scoring 53/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 19, recommendation 62). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Zealand Pharma official site
Zealand Pharma was founded in 1998. Zealand Pharma operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Zealand Pharma is headquartered in Glostrup. Zealand Pharma operates in the Healthcare category.
Sources: Wikidata
Zealand Pharma discovers, designs, and develops innovative peptide-based and small molecule medicines aimed at treating obesity and metabolic health conditions, including Congenital Hyperinsulinism and Short Bowel Syndrome. The company builds a pipeline of therapeutics intended to improve long-term health outcomes for patients with these conditions.
Sources: Zealand Pharma official site
Zealand Pharma scores 62/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Zealand Pharma official site
Zealand Pharma develops peptide-based and small molecule medicines targeting obesity and metabolic health, as well as treatments for Congenital Hyperinsulinism and Short Bowel Syndrome. The company's offerings are primarily in the form of a drug development pipeline rather than consumer products.
Sources: Zealand Pharma official site
Zealand Pharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Zealand Pharma official site
Zealand Pharma is owned by or part of Legg Mason. Zealand Pharma operates in the Healthcare category.
Sources: Wikidata
Zealand Pharma's therapies are intended for patients suffering from obesity and metabolic health conditions, including rarer disorders like Congenital Hyperinsulinism and Short Bowel Syndrome. The company also engages with healthcare providers, biotech partners, and investors interested in peptide-based drug development.
Sources: Zealand Pharma official site
Zealand Pharma is known for its specialized expertise in peptide-based drug development, particularly in the field of obesity and metabolic health. The company has built a pipeline of therapeutics targeting these areas, along with treatments for rarer conditions such as Congenital Hyperinsulinism and Short Bowel Syndrome.
Sources: Zealand Pharma official site
Ranked closest to Zealand Pharma: Zanda Health (77/100), Press Ganey (77/100), Adimab (76/100), Adit (76/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).